secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-125384
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema Pharma Q3 net loss $34.6M; cash $214.8M; OP-3136 IND on track
-------------------------------------------------------------------

- Q3 2024 net loss $34.6M vs $21.5M in Q3 2023; GAAP R&D $33.2M (up from $19.5M).
- Cash, equivalents, marketable securities $214.8M as of Sep 30, 2024; no revenue reported.
- OPERA-01 Phase 3 palazestrant monotherapy enrolling; top-line readout expected 2026.
- IND submission for KAT6 inhibitor OP-3136 expected before year-end; Phase 1 start early 2025.
- Updated Phase 2 palazestrant + ribociclib data to be presented at SABCS December 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000095017024125384/0000950170-24-125384-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000095017024125384/olma-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125384

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer